ArticleFrontiers in medicine2026
Identification and validation of a nomogram for psoriasis diagnosis: a novel biomarker combination with stable high expression in the early stage.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Psoriasis is a complex chronic inflammatory skin disease. While typical cases are often diagnosed based on clinical features, achieving objective assessment of disease activity and precise early-stage identification remains a clinical focus. This study aims to evaluate the diagnostic value of monocytes (MONO), Orosomucoid-1 (ORM1), Orosomucoid-2 (ORM2), and Alpha-1-acid glycoprotein (AGP), and to develop a nomogram for the objective and early identification of psoriasis. Methods: This retrospective case-control study included 140 participants, comprising 70 patients with psoriasis confirmed by the dermatology department and 70 healthy individuals who underwent routine health examinations during the same period. Demographic, clinical, and laboratory data (including MONO, ORM1, ORM2, and AGP) were collected for all participants. Potential risk factors were initially screened using univariate Logistic regression, followed by feature selection via the combination of Lasso regression and Boruta algorithm to identify features with the highest predictive value. Restricted cubic spline (RCS) plots were utilized to visually illustrate the non-linear associations between the selected variables and the risk of psoriasis onset. Finally, the selected features were incorporated into a multivariate Logistic regression model to determine the independent risk factors, and a diagnostic nomogram was constructed accordingly. Results: Based on the results of univariate analysis, LASSO regression and Boruta algorithm, we ultimately selected four key variables, namely MONO, ORM1, ORM2 and AGP, for the construction of the subsequent multivariate diagnostic model. The calibration curve of the model showed that the actual probability was highly consistent with the predicted probability, indicating that the model had good calibration performance. The receiver operating characteristic (ROC) curve indicated that the overall predictive ability of the model was excellent, with an area under curve (AUC) of 0.888 (95% CI: 0.835-0.941). In addition, the ROC curves of each variable analyzed separately showed that ORM2 (AUC = 0.777), ORM1 (AUC = 0.720), MONO (AUC = 0.638) and AGP (AUC = 0.673) all had different degrees of predictive ability for the risk of psoriasis. Conclusion: The novel biomarker combinations with stable and high expression in the early stage have shown great potential in the research of psoriasis. These research results should be applied to clinical.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.